Immunai Recognized by Fast Company’s 2021 World Changing Ideas Awards

Immunai, a New York and Tel Aviv-based biotech company, today announced that it has been recognized as part of Fast Company’s World Changing Ideas Awards. The awards honor the businesses, policies, projects, and concepts that are actively engaged and deeply committed to pursuing innovation when it comes to solving health and climate crises, social injustice, or economic inequality. Immunai has been recognized with an honorable mention in the award’s AI and Data category for its efforts to reprogram immunity. 

Immunai’s end-to-end platform combines the latest advances in single-cell genomics, bioinformatics, and artificial intelligence to measure the immune system at high resolution, at an unprecedented scale. By collaborating with Fortune 100 pharmaceutical companies and leading academic institutions like Stanford, Baylor College of Medicine, and Harvard, Immunai helps power target discovery and improves therapy development. 

Immunai joins a notable group of companies recognized this year: TruEra, AMP Robotics, Atomwise, Diversio, Phoenix Motorcars, Brightseed, Genuity Science, Feinstein Institutes for Medical Research, Curi Bio, nference, GHGSat, Salesforce, and The Trevor Project. The 2021 awards received more than 4,000 entries across transportation, education, food, politics, technology, and more. Entries were submitted from across the globe, from Brazil to Denmark to Vietnam.

“Since our launch from stealth this time last year, our team has partnered with Fortune 100 companies and leading academic institutions and hospitals to elucidate immunological mysteries, discover novel drug targets and map the immune system to a degree that allows us to reprogram it with more targeted therapies,” said Immunai’s CEO and Co-founder, Noam Solomon. “I’m proud of what our team has accomplished and am grateful for this award’s validation of our technology and innovation.”

This award comes on the heels of Immunai’s recent announcement of its acquisition of Dropprint Genomics and the expansion of its leadership team. Both the acquisition and new hires will advance the company’s work in functional genomics with the goal of better supporting discovery, prioritization, and development of new therapies and drug combinations.

For more information about Immunai’s mission to reprogram the immune system and improve patient outcomes, please visit immunai.com. 

About Immunai

Immunai is on a mission to reprogram the immune system to advance personalized medicine to better detect, diagnose, and treat disease. The team is composed of genomics, machine learning, bioinformatics, immunology, and software engineering experts and is headquartered in New York City, with offices in San Francisco and Tel Aviv. The company has raised $80M in funding to-date from Viola Ventures, TLV Partners, Schusterman Family Investments, Duquesne Family Office, Catalio Capital Management, and Dexcel Pharma.

About the World Changing Ideas Awards

World Changing Ideas is one of Fast Company’s major annual awards programs and is focused on social good, seeking to elevate finished products and brave concepts that make the world better. A panel of judges from across sectors choose winners, finalists, and honorable mentions based on feasibility and the potential for impact. With the goals of awarding ingenuity and fostering innovation, Fast Company draws attention to ideas with great potential and helps them expand their reach to inspire more people to start working on solving the problems that affect us all.

Contact Information

Kayla Abbassi

Director

VSC for Immunai

kaylaa@vsc.co